461 related articles for article (PubMed ID: 27184802)
1. Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study.
Ngalesoni FN; Ruhago GM; Mori AT; Robberstad B; Norheim OF
BMC Health Serv Res; 2016 May; 16():185. PubMed ID: 27184802
[TBL] [Abstract][Full Text] [Related]
2. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis.
Gaziano TA; Opie LH; Weinstein MC
Lancet; 2006 Aug; 368(9536):679-86. PubMed ID: 16920473
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.
Barrios V; Kaskens L; Castellano JM; Cosin-Sales J; Ruiz JE; Zsolt I; Fuster V; Gracia A
Rev Esp Cardiol (Engl Ed); 2017 Jan; 70(1):42-49. PubMed ID: 27474481
[TBL] [Abstract][Full Text] [Related]
5. Prevention and treatment of cardiovascular disease in Ethiopia: a cost-effectiveness analysis.
Tolla MT; Norheim OF; Memirie ST; Abdisa SG; Ababulgu A; Jerene D; Bertram M; Strand K; Verguet S; Johansson KA
Cost Eff Resour Alloc; 2016; 14():10. PubMed ID: 27524939
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of a cardiovascular disease primary prevention programme in a primary health care setting. Results of the Polish part of the EUROACTION project.
Sović N; Pająk A; Jankowski P; Duenas A; Kawecka-Jaszcz K; Wolfshaut-Wolak R; Stepaniak U; Kawalec P
Kardiol Pol; 2013; 71(7):702-11. PubMed ID: 23907903
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.
Schädlich PK; Brecht JG; Rangoonwala B; Huppertz E
Pharmacoeconomics; 2004; 22(15):955-73. PubMed ID: 15449961
[TBL] [Abstract][Full Text] [Related]
8. Cost-utility of empagliflozin in patients with type 2 diabetes at high cardiovascular risk.
Nguyen E; Coleman CI; Nair S; Weeda ER
J Diabetes Complications; 2018 Feb; 32(2):210-215. PubMed ID: 29157870
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of two versus three or more doses of intermittent preventive treatment for malaria during pregnancy in sub-Saharan Africa: a modelling study of meta-analysis and cost data.
Fernandes S; Sicuri E; Kayentao K; van Eijk AM; Hill J; Webster J; Were V; Akazili J; Madanitsa M; ter Kuile FO; Hanson K
Lancet Glob Health; 2015 Mar; 3(3):e143-53. PubMed ID: 25701992
[TBL] [Abstract][Full Text] [Related]
10. A health economic evaluation of aspirin in the primary prevention of cardiovascular disease in Japan.
Tsutani K; Igarashi A; Fujikawa K; Evers T; Kubin M; Lamotte M; Annemans L
Intern Med; 2007; 46(4):157-62. PubMed ID: 17301509
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of improved treatment services for sexually transmitted diseases in preventing HIV-1 infection in Mwanza Region, Tanzania.
Gilson L; Mkanje R; Grosskurth H; Mosha F; Picard J; Gavyole A; Todd J; Mayaud P; Swai R; Fransen L; Mabey D; Mills A; Hayes R
Lancet; 1997 Dec 20-27; 350(9094):1805-9. PubMed ID: 9428251
[TBL] [Abstract][Full Text] [Related]
12. Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.
Cobiac LJ; Magnus A; Barendregt JJ; Carter R; Vos T
BMC Public Health; 2012 Jun; 12():398. PubMed ID: 22657090
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of medical interventions to prevent cardiovascular disease in a sub-Saharan African country--the case of Tanzania.
Robberstad B; Hemed Y; Norheim OF
Cost Eff Resour Alloc; 2007 Feb; 5():3. PubMed ID: 17316431
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of population-based tobacco control strategies in the prevention of cardiovascular diseases in Tanzania.
Ngalesoni F; Ruhago G; Mayige M; Oliveira TC; Robberstad B; Norheim OF; Higashi H
PLoS One; 2017; 12(8):e0182113. PubMed ID: 28767722
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.
Rosen AB; Hamel MB; Weinstein MC; Cutler DM; Fendrick AM; Vijan S
Ann Intern Med; 2005 Jul; 143(2):89-99. PubMed ID: 16027450
[TBL] [Abstract][Full Text] [Related]
16. Cost-Effectiveness of a Statewide Campaign to Promote Aspirin Use for Primary Prevention of Cardiovascular Disease.
Michaud TL; Abraham J; Jalal H; Luepker RV; Duval S; Hirsch AT
J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26702086
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
[TBL] [Abstract][Full Text] [Related]
18. Estimation of the burden of cardiovascular disease attributable to modifiable risk factors and cost-effectiveness analysis of preventative interventions to reduce this burden in Argentina.
Rubinstein A; Colantonio L; Bardach A; Caporale J; Martí SG; Kopitowski K; Alcaraz A; Gibbons L; Augustovski F; Pichón-Rivière A
BMC Public Health; 2010 Oct; 10():627. PubMed ID: 20961456
[TBL] [Abstract][Full Text] [Related]
19. Which patients should receive aspirin for primary prevention of cardiovascular disease? An economic evaluation.
Annemans L; Lamotte M; Kubin M; Evers T; Verheugt FW
Int J Clin Pract; 2006 Sep; 60(9):1129-37. PubMed ID: 16939558
[TBL] [Abstract][Full Text] [Related]
20. Equity impact analysis of medical approaches to cardiovascular diseases prevention in Tanzania.
Ngalesoni FN; Ruhago GM; Mori AT; Robberstad B; Norheim OF
Soc Sci Med; 2016 Dec; 170():208-217. PubMed ID: 27590271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
